Literature DB >> 27472448

Corrigendum: The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.

Xin Wang, Magdalena Mazurkiewicz, Ellin-Kristina Hillert, Maria Hägg Olofsson, Stefan Pierrou, Per Hillertz, Joachim Gullbo, Karthik Selvaraju, Aneel Paulus, Sharoon Akhtar, Felicitas Bossler, Asher Chanan Khan, Stig Linder, Padraig D'Arcy.   

Abstract

Entities:  

Year:  2016        PMID: 27472448      PMCID: PMC4966493          DOI: 10.1038/srep30667

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


× No keyword cloud information.
The Acknowledgements section in this Article is incomplete: “We are grateful to Hans Rosén and Per Hagmar (Vivolux AB) for discussions and study support and to Marina Ciomei (Accelera, Nerviano, Italy) for performance of animal studies. We are grateful to Ingrid Holmberg for artwork. We acknowledge Cancerfonden, Radiumhemmets forskningsfonder, Vetenskapsrådet, Barncancerfonden for support.” should read: “We are grateful to Hans Rosén and Per Hagmar (Vivolux AB) for discussions and study support and to Marina Ciomei (Accelera, Nerviano, Italy) for performance of animal studies. We are grateful to Ingrid Holmberg for artwork. We acknowledge Cancerfonden, Radiumhemmets forskningsfonder, Vetenskapsrådet, Barncancerfonden for support. We would like to acknowledge support from the Mayo Clinic Multiple Myeloma SPORE (P50 CA186781-01A1, Aneel Paulus) and the University of Iowa/Mayo Clinic Lymphoma SPORE (P50 CA097274, Aneel Paulus)”.
  2 in total

Review 1.  Targeting deubiquitinating enzymes in cancer stem cells.

Authors:  Hu Lei; Huizhuang Shan; Yingli Wu
Journal:  Cancer Cell Int       Date:  2017-11-03       Impact factor: 5.722

2.  Choreographing atomic motions of macromolecular machines in action: Towards dynamics-based drug discovery.

Authors:  Shitao Zou; Youdong Mao
Journal:  Clin Transl Med       Date:  2022-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.